Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer (mHSPC).
The ARCHES study randomized patients with mHSPC to receive androgen deprivation therapy with enzalutamide (Xtandi) or placebo.
The trial was designed to evaluate all men with mHSPC rather than evaluating 1 specific subtype, says Azad.
Notably, the study included men with low- and high-volume mHSPC, men with newly diagnosed and relapsed/refractory mHSPC, and men who previously received docetaxel.
Additionally, ARCHES was a multicenter, international study; thus, the data are widely applicable, Azad concludes.